Dyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company develops a program that will focus on using antibody-oligo conjugates to block the repetitive DNA mutations that cause the disease myotonic dystrophy type 1.
|HQ||Waltham, MA, US||Map|
Dyne Therapeutics total Funding
Dyne Therapeutics latest funding size
Time since last funding
|9 months ago|
Dyne Therapeutics investors
|Atlas Venture, MPM Capital, Forbion Capital Partners, Franklin Templeton, Vida Ventures, Surveyor Capital, Logos Capital, Management Company|
Dyne Therapeutics has 465 Twitter Followers. The number of followers has increased 5.4% month over month and increased 12.1% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Dyne Therapeutics founded?
Dyne Therapeutics was founded in 2018.
Who are Dyne Therapeutics key executives?
Dyne Therapeutics's key executives are Joshua Brumm, Catherine Stehman-Breen and Romesh Subramanian.
How many employees does Dyne Therapeutics have?
Dyne Therapeutics has 56 employees.
Who are Dyne Therapeutics competitors?
Competitors of Dyne Therapeutics include Precigen, Ambrx and ProQR Therapeutics.
Where is Dyne Therapeutics headquarters?
Dyne Therapeutics headquarters is located at 830 Winter St, Waltham.
Where are Dyne Therapeutics offices?
Dyne Therapeutics has an office in Waltham.
How many offices does Dyne Therapeutics have?
Dyne Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies